Nonadherence could be getting in the way of your patients reaching and remaining at LDL-C target^1-5

49% more cardiovascular events* in patients who failed to reach LDL-C target^6†

The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.

*An event may include myocardial infarction, unstable angina, revascularization, stroke, and/or acute limb ischemia resulting from coronary, cerebrovascular, or peripheral artery disease.<sup>7

†</sup>Based on study (N=38,110,734) data that evaluated the annual cardiovascular event rates in a subset of guideline-defined high-risk patients of the Family Heart Database, which comprises diagnostic, procedure, lab, and prescription data from claims in the US from 2012 to 2021.⁶

Many patients struggle to adhere to self-administered treatments

^‡From an analysis of a large IQVIA open claims dataset of patients (N=72,001) between September 2020 to January 2023.^9
§In a retrospective cohort study of pharmacy and health plan claims of patients who initiated PCSK9 mAbs (N=13,151) between January 1, 2016 and June 30, 2016, who were followed for a minimum of 6 months after their first prescription fill. Discontinuation was defined as the gap of 60 days or more between the last day of supply of one prescription and the start of the next prescription. Specific reasons for discontinuation were unknown; however, it could have been due to poor tolerability, noncompliance, unwillingness to perform injections, and insurance or cost issues. Gaps in therapy were derived from actual prescription fill data.⁸

^‖Questionnaire conducted in 113 physician providers in the United States from December 2016 to July 2018 as part of GOULD, a multicenter observational registry.¹⁰

Patients may be nonadherent to statins and self-administered treatments for many reasons^11,12:

• Treatment side effects
• Frequent dosing burden
• Cost
• Fear/avoidance of self-injections
• Inconvenience
• Lack of motivation/belief in efficacy
• Polypharmacy challenges
• Statin intolerance